Table 6.
Actuarial Late ≥ grade 2 GI Toxicity* and Univariate Analysis in Subgroup Treated to Pelvic Lymph Nodes
| Variable | 3-year KM | 5-year KM | p-value | HR (95% CI) |
|---|---|---|---|---|
| AD duration | ||||
| STAD | 15% | 17% | 0.8 | 0.9 (0.5–1.7) |
| LTAD | 16 | 16 | 1 | |
| ≤ 1 year | 13 | 13 | ||
| > 1 – 5 | 18 | 18 | ||
| > 5 | 0 | 0 | ||
| T-stage | ||||
| T1 | 9 | 9 | 0.2 | 1 |
| T2 | 19 | 21 | 2.4 (0.8–7) | |
| T3 | 15 | 15 | 1.9 (0.6–5.9) | |
| Diabetes | ||||
| Yes | 16 | 16 | 0.9 | 1 |
| No | 16 | 17 | 1 (0.4–2.2) | |
| Gleason Score | ||||
| 2–6 | 17 | 17 | 1.0 | 1 |
| 7 | 18 | 18 | 1.0 (0.5–2.2) | |
| 8–10 | 13 | 15 | 1.0 (0.5–2.2) | |
| iPSA | ||||
| <10 | 14 | 14 | 0.9 | 1 |
| 10–20 | 16 | 19 | 1.1 (0.5–2.6) | |
| >20 | 18 | 18 | 1.1 (0.5–2.2) | |
| Treatment | ||||
| IMRT | 7 | 7 | 0.02 | 1 |
| 3DCRT | 20 | 21 | 2.5(1.1–6.5) | |
| BF status | ||||
| Yes | 20 | 20 | 0.6 | 1 |
| No | 17 | 17 | 0.8 (0.4–1.7) | |
| Increasing Age (continuous) | NA | NA | 0.4 | |
| Increasing RT Dose (continous) | NA | NA | 0.09 | |
| Photon Energy | 0.3 | |||
| < 10 MV | 9 | 9 | 1 | |
| 10 – 14 | 12 | 15 | 1.1 (0.1–8.2) | |
| > 14 | 19 | 19 | 1.7 (0.2–12.7) |
Abbreviations: iPSA= initial prostate specific antigen; AD= androgen deprivation; STAD= short term androgen deprivation; LTAD= long-term androgen deprivation; SV= seminal vesicles; BF= biochemical failure; KM= Kaplan-Meier
*
Fox Chase modified LENT scale